Literature DB >> 1912589

T-cell depletion of HLA-identical transplants in leukemia.

A M Marmont1, M M Horowitz, R P Gale, K Sobocinski, R C Ash, D W van Bekkum, R E Champlin, K A Dicke, J M Goldman, R A Good.   

Abstract

We analyzed the effects of T-cell depletion on the outcome of HLA-identical sibling bone marrow transplants for leukemia by comparing 731 T-cell-depleted transplants with 2,480 non-T-cell-depleted transplants. T-cell depletion decreased acute graft-versus-host disease (GVHD) (relative risk [RR] 0.45; P less than .0001) and chronic (GVHD) (RR 0.56; P less than .0001). However, it increased graft failure (RR 9.29; P less than .0001). Leukemia relapse also was increased. In first remission acute leukemia or chronic phase chronic myelogenous leukemia, leukemia relapse was 2.75 times more likely after T-cell-depleted transplants (P less than .0001). T-cell depletion increased the risk of treatment failure (RR 1.35; P less than .0003) and decreased leukemia-free survival. We also studied controllable variables associated with outcome of T-cell-depleted transplants. The unique findings were that among recipients of T-cell-depleted transplants for early leukemia, radiation doses greater than or equal to 11 Gy (RR 0.54; P less than .01), dose rates greater than 14 cGy/min (RR 0.56; P less than .002), and additional posttransplant immune suppression with cyclosporine alone (RR 0.53; P less than .0006) or cyclosporine plus methotrexate (RR 0.36; P less than .01) were associated with fewer treatment failures. Use of monoclonal antibodies rather than physical techniques for T-cell depletion (RR 2.01; P less than .03) and fractionated radiation (RR 1.69; P less than .05) were associated with increased treatment failure and lower leukemia-free survival. These data may be useful in designing strategies to improve results of T-cell-depleted transplants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912589

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  114 in total

Review 1.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Leukodystrophy and bone marrow transplantation: role of mixed hematopoietic chimerism.

Authors:  C L Kaufman; S T Ildstad
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

3.  Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages.

Authors:  Stefan O Schönland; Consuelo Lopez; Thomas Widmann; Julia Zimmer; Ewa Bryl; Jörg J Goronzy; Cornelia M Weyand
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-24       Impact factor: 11.205

Review 4.  Prevention of graft-vs.-host disease.

Authors:  Andrew R Rezvani; Rainer F Storb
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

5.  Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

Authors:  E J Claret; E P Alyea; E Orsini; C C Pickett; H Collins; Y Wang; D Neuberg; R J Soiffer; J Ritz
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 6.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

Review 7.  Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care.

Authors:  Razvan Diaconescu; Rainer Storb
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-28       Impact factor: 4.553

Review 8.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

9.  Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.

Authors:  Sarah Nicholls; Karen P Piper; Fiyaz Mohammed; Timothy R Dafforn; Stefan Tenzer; Mahboob Salim; Premini Mahendra; Charles Craddock; Peter van Endert; Hansjörg Schild; Mark Cobbold; Victor H Engelhard; Paul A H Moss; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

10.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.

Authors:  Y Zeng; J Stokes; S Hahn; E Hoffman; E Katsanis
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.